Answers are grounded in this paper and cite their sources.
Meta-analysis reveals notable lung and heart toxicities in metastatic breast cancer treated with trastuzumab deruxtecan, highlighting the need for multidisciplinary toxicity monitoring.
In this meta-analysis of 1970 patients with mBC, treatment with T-DXd was associated with a 11.7% incidence of ILD, 7.7% incidence of prolonged QTi, and 1.9% incidence of reduced LVEF. Early detection and management of T-DXd-related toxicity by a multidisciplinary team may ultimately improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Soares et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: